Merck entered into an exclusive licensing deal with Hanmi Pharmaceutical for the development, manufacture and commercialization of efinopegdutide for nonalcoholic steatohepatitis (NASH).
GlaxoSmithKline and Sanofi struck a $2.1 billion deal with the U.S. government’s Operation Warp Speed program to supply an initial 100 million doses of a Covid-19 vaccine candidate under development by the two companies.
Brussels, Belgium-based UCB entered into a global licensing deal with Roche and Genentech to develop and commercialize UCB0107 in Alzheimer’s disease.
AstraZeneca inked a global development and commercialization deal with Daiichi Sankyo for DS-1062, a trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate for multiple cancer types.
Covid-19 put many businesses on hold, but not biotech. This sector is growing at record speeds, and only a small portion of the capital deals are related to the pandemic.
The U.S. government set a benchmark for COVID-19 vaccine pricing that will likely pressure other manufacturers to set similar prices, industry analysts told Reuters.
Sanofi is rumored to have a $50 billion budget for mergers and acquisitions and is taking a look at U.S.-based biotech companies, including South San Francisco-based Principia Biopharma.
Roche struck a $1.7 billion cancer drug pact with Blueprint Medicines, as advances in genetic testing for rare mutations drive lucrative deals for expensive treatments.
Ovid Therapeutics and Angelini Pharma entered into an exclusive license agreement to develop, manufacture and commercialize OV101 for the treatment of Angelman syndrome in Europe.
Kymera Therapeutics entered a strategic collaboration deal with Sanofi focused on developing and commercializing protein degrader therapies that target IRAK4 in immune-inflammatory diseases, such as rheumatoid arthritis.